User profiles for "author:A.-M. Mes-Masson"
Anne-Marie Mes-MassonProfessor, Departement of Medicine, Université de Montréal Verified email at umontreal.ca Cited by 49769 |
[HTML][HTML] ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
KC Wiegand, SP Shah, OM Al-Agha… - … England Journal of …, 2010 - Mass Medical Soc
Background Ovarian clear-cell and endometrioid carcinomas may arise from endometriosis,
but the molecular events involved in this transformation have not been described. Methods …
but the molecular events involved in this transformation have not been described. Methods …
[HTML][HTML] Mutation of FOXL2 in Granulosa-Cell Tumors of the Ovary
Background Granulosa-cell tumors (GCTs) are the most common type of malignant ovarian
sex cord–stromal tumor (SCST). The pathogenesis of these tumors is unknown. Moreover …
sex cord–stromal tumor (SCST). The pathogenesis of these tumors is unknown. Moreover …
[HTML][HTML] Ran GTPase: a key player in tumor progression and metastasis
Z Boudhraa, E Carmona, D Provencher… - Frontiers in Cell and …, 2020 - frontiersin.org
Ran (Ras-related nuclear protein) GTPase is a member of the Ras superfamily. Like all the
GTPases, Ran cycles between an active (GTP-bound) and inactive (GDP-bound) state …
GTPases, Ran cycles between an active (GTP-bound) and inactive (GDP-bound) state …
The Chronic Myelogenous Leukemia-Specific P210 Protein Is the Product of the bcr/abl Hybrid Gene
Chronic myelogenous leukemia (CML) is a human disease associated with a consistent
chromosomal translocation that results in sequences from the c-abl locus on chromosome 9 …
chromosomal translocation that results in sequences from the c-abl locus on chromosome 9 …
Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma
M Köbel, AM Piskorz, S Lee, S Lui… - The Journal of …, 2016 - Wiley Online Library
TP53 mutations are ubiquitous in high‐grade serous ovarian carcinomas (HGSOC), and the
presence of TP53 mutation discriminates between high and low‐grade serous carcinomas …
presence of TP53 mutation discriminates between high and low‐grade serous carcinomas …
Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes
We studied the whole-genome point mutation and structural variation patterns of 133 tumors
(59 high-grade serous (HGSC), 35 clear cell (CCOC), 29 endometrioid (ENOC), and 10 …
(59 high-grade serous (HGSC), 35 clear cell (CCOC), 29 endometrioid (ENOC), and 10 …
Spatially mapping the immune landscape of melanoma using imaging mass cytometry
Melanoma is an immunogenic cancer with a high response rate to immune checkpoint
inhibitors (ICIs). It harbors a high mutation burden compared with other cancers and, as a …
inhibitors (ICIs). It harbors a high mutation burden compared with other cancers and, as a …
Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC)
M Zietarska, CM Maugard… - … in cooperation with …, 2007 - Wiley Online Library
Epithelial ovarian cancer (EOC) cell lines are useful tools for the molecular and biological
characterization of ovarian cancer. The use of an in vitro multidimensional (3‐D) culture …
characterization of ovarian cancer. The use of an in vitro multidimensional (3‐D) culture …
Characterization of four novel epithelial ovarian cancer cell lines
DM Provencher, H Lounis, L Champoux… - In vitro cellular & …, 2000 - JSTOR
Dear Editor: Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy.
EOCs originate from either the surface epithelium itself or from the crypts or inclusion cysts …
EOCs originate from either the surface epithelium itself or from the crypts or inclusion cysts …
CD73 is associated with poor prognosis in high-grade serous ovarian cancer
M Turcotte, K Spring, S Pommey, G Chouinard… - Cancer research, 2015 - AACR
The cell surface nucleotidase CD73 is an immunosuppressive enzyme involved in tumor
progression and metastasis. Although preclinical studies suggest that CD73 can be targeted …
progression and metastasis. Although preclinical studies suggest that CD73 can be targeted …